Mod GRF 1-29
Modified Growth Hormone Releasing Factor 1-29
A modified version of GHRH (sermorelin) with enhanced stability. Also known as CJC-1295 without DAC.
Typical Cost
$40-80/vial (2mg)
Status
Research
Peptide Profile
Mod GRF 1-29
Mechanism of Action
Stimulates growth hormone release from pituitary. Shorter half-life than CJC-1295 with DAC requires multiple daily dosing but more closely mimics natural GH pulsatility.
Common Dosages
subcutaneous
100-300mcg
1-3x daily · 8-12 weeks
Benefits
Increased growth hormone
More natural pulsatility
Fat loss
Muscle preservation
Side Effects
Water retention
Injection site reactions
Numbness/tingling
Key Research
Mod GRF and GH stimulation
Demonstrated effective GH stimulation with pulsatile pattern
Regulatory Status
Research chemical only. Not FDA-approved.
Contraindications
- ⚠Active cancer
- ⚠Diabetic retinopathy
- ⚠Pregnancy/breastfeeding
GLP-1 users may prefer alternatives without peptide complexity. SeraVia formulations support metabolic health directly.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.